Reocclusion: the flip side of coronary thrombolysis
- PMID: 8613601
- DOI: 10.1016/0735-1097(95)00492-0
Reocclusion: the flip side of coronary thrombolysis
Abstract
Since the introduction of thrombolytic therapy for acute myocardial infarction, the incidence of coronary artery reocclusion has been intensively studied. Also, the prediction and diagnosis of reocclusion by angiographic and clinical variables, as well its invasive and pharmacologic prevention, have gained much attention. By angiographic definition, reocclusion requires three angiographic observations: one with an occluded artery, one with a reperfused artery and a third for the assessment of subsequent occlusion (true reocclusion). Since the introduction of early intravenous reperfusion therapy, most studies use only two angiograms: one with a patent and one with a nonpatent infarct-related artery. A search for all published reocclusion studies revealed 61 studies (6,061 patients) with at least two angiograms. The median time interval between the first angiogram after thrombolysis and the second was 16 days (range 0.1 to 365). Reocclusion was observed in 666 (11%) of 6,061 cases. Interestingly, the 28 true reocclusion studies showed an incidence of reocclusion of 16 +/- 10% (mean +/- SD), and the 33 studies with only two angiograms 10 +/- 8% (p=0.04), suggesting that proven initial occlusion of the infarct-related artery is a risk factor for reocclusion after successful thrombolysis. The other predictors for reocclusion are probably severity of residual stenosis of the infarct-related artery after thrombolysis and perhaps the flow state after lysis. Reocclusion is most frequently seen in the early weeks after thrombolysis. The clinical course in patients with reocclusion is more complicated than in those without this complication. Left ventricular contractile recovery after thrombolysis is hampered by reocclusion. Routine invasive strategies have not been proven effective against reocclusion. In the prevention of reocclusion, both antiplatelet and antithrombin strategies have been tested, including hirudin and hirulog, but the safety of these agents in thrombolysis is still questionable. Thus, reocclusion after thrombolysis is an early phenomenon and is more frequent after proven initial occlusion of the infarct-related artery. Reocclusion can be predicted by angiography after thrombolysis. Because reocclusion is detrimental, strategies to prevent it should be developed and carried out after thrombolytic therapy for acute myocardial infarction as soon as they are deemed safe.
Similar articles
-
A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.J Am Coll Cardiol. 1994 Apr;23(5):993-1003. doi: 10.1016/0735-1097(94)90581-9. J Am Coll Cardiol. 1994. PMID: 8144799 Clinical Trial.
-
Direct thrombin inhibition and thrombolytic therapy: rationale for the Hirulog and Early Reperfusion/Occlusion (HERO-2) trial.Am J Cardiol. 1998 Oct 22;82(8B):57P-62P. doi: 10.1016/s0002-9149(98)00663-8. Am J Cardiol. 1998. PMID: 9809893 Clinical Trial.
-
Hirudin (desirudin) and Hirulog (bivalirudin) in acute ischaemic syndromes and the rationale for the Hirulog/Early Reperfusion Occlusion (HERO-2) Study.Aust N Z J Med. 1998 Aug;28(4):551-4. doi: 10.1111/j.1445-5994.1998.tb02109.x. Aust N Z J Med. 1998. PMID: 9777138 Clinical Trial.
-
Direct thrombin inhibitors as adjuncts to thrombolytic therapy.Curr Cardiol Rep. 1999 Sep;1(3):184-91. doi: 10.1007/s11886-999-0021-0. Curr Cardiol Rep. 1999. PMID: 10980840 Review.
-
Role of new antiplatelet agents as adjunctive therapies in thrombolysis.Am J Cardiol. 1991 Jan 25;67(3):12A-18A. doi: 10.1016/0002-9149(91)90083-w. Am J Cardiol. 1991. PMID: 1990781 Review.
Cited by
-
In vitro fibrinolysis and antithrombosis characterizations of novel recombinant microplasminogen with RGD and GPRP peptides.J Thromb Thrombolysis. 2016 Jul;42(1):118-26. doi: 10.1007/s11239-016-1334-7. J Thromb Thrombolysis. 2016. PMID: 26814674
-
Impact of early accelerated dose tissue plasminogen activator on in-hospital patency of the infarcted vessel in patients with acute right ventricular infarction.Heart. 1997 Jun;77(6):512-6. doi: 10.1136/hrt.77.6.512. Heart. 1997. PMID: 9227293 Free PMC article.
-
Optimizing the use of thrombolytics in ST-segment elevation myocardial infarction.Drugs. 2009 Oct 1;69(14):1945-66. doi: 10.2165/11317670-000000000-00000. Drugs. 2009. PMID: 19747010 Review.
-
Highly effective fibrinolysis by a sequential synergistic combination of mini-dose tPA plus low-dose mutant proUK.PLoS One. 2015 Mar 26;10(3):e0122018. doi: 10.1371/journal.pone.0122018. eCollection 2015. PLoS One. 2015. PMID: 25811605 Free PMC article.
-
Prehospital fibrinolysis with dual antiplatelet therapy in ST-elevation acute myocardial infarction: a substudy of the randomized double blind CLARITY-TIMI 28 trial.J Thromb Thrombolysis. 2007 Jun;23(3):173-9. doi: 10.1007/s11239-006-9047-y. Epub 2006 Dec 9. J Thromb Thrombolysis. 2007. PMID: 17160548 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical